Tumor digests from breast, colon, head and neck, lung, and ovarian cancer patients were screened for their TA-pDC content using flow cytometry based on expression of CD123 and CD303 (Figure 1A and Supplementary Table S1). This evidence concerns the gene IL3RA and neoplasm.